The telehealth system provider is going public in an $742m upsized offering that will enable Philips, Allianz, Teva and Takeda to exit.

The kidney dialysis technology provider has added about $36m to close its initial public offering, it shares having more than doubled in price.

Tencent is the largest shareholder of short-form video app developer Kuaishou, which is reportedly looking to boost its valuation to $50bn in a January offering.

Dell's stake in the software release technology provider is sized at almost $490m following an initial public offering in which it floated well above its range.

The data services software provider had raised more than $55m from investors including NetApp, Cisco Investments, Hewlett Packard Enterprise and GE Ventures.

Lilly Asia Ventures achieved an exit as the gastrointestinal and liver disease drug developer priced its initial public offering in the middle of its range.

Salesforce Ventures will invest another $250m as the data management software provider floated above its range at a valuation just short of $29bn.

Lennar, SoftBank, Access Industries and Alphabet are set to score exits from the real estate transaction manager, valued at $4.8bn in the deal.

Baxter International scored an exit as dialysis machine developer Outset Medical floated above its range in an upsized offering.

Astellas and Celgene-backed immuno-oncology therapy developer Oncorus has filed to raise up to $86.3m following more than $150m in funding.